Myeloma Canada, along with thousands from the global hematology community, had the privilege of following the American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 – June 4, 2023) and attending the European Hematology Association (EHA) Hybrid Congress (June 8-11, 2023) to hear from leading myeloma experts about the latest progress in myeloma research.

Once again, similar to our last myeloma research update from the 64th American Society of Hematology (ASH) Annual Meeting and Exposition , the main focus of the myeloma research presented was on chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody treatments.

Below are some of the therapies discussed:

•             Ciltacabtagene autoleucel (Cilta-cel; Carvykti)

•             Idecabtagene Vicleucel (Ide-cel; Abecma)

•             Teclistamab (TEC; Tecvayli)

•             Talquetamab (TAL)

•             Elranatamab

•             Linvoseltamab (REGN5458)

•             Belantamab mafodotin (belamaf)

•             Selinexor (Xpovio)

•             CAEL-101 in amyloid light-chain (AL) amyloidosis

For a non-exhaustive global overview, please consult the document here.